Conventional versus novel antipsychotics: Changing concepts and clinical implications

Journal of Psychiatry and Neuroscience

Volumn 24, Issue 5, 1999, Pages 431-441

  Remington, Gary ^a,c   Chong, Siow Ann ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE OF MENTAL HEALTH   (Singapore)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CONFERENCE PAPER; DRUG EFFICACY; DRUG RESEARCH; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0033377929     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (101)

1. 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997;154(11):1525-9.
2. Casey DE. Extrapyramidal syndromes in non-human primates; typical and atypical neuroleptics. Psychopharmacol Bull 1991; 27(1):47-50.
3. Carpenter WT Jr, Heinrichs DW, Wagman AMI. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1998;145(5):578-83.
4. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16(4):551-61.
5. Holland D, Watanabe MD, Sharma R. Atypical antipsychotics. Psychiatr Med 1991;9(4):5-24.
6. Casey DE. What makes a neuroleptic atypical? In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press; 1992. p. 241-51.
7. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry 1993;163(Suppl 22):7-18.
8. Kerwin RW. The new atypical antipsychotics. A lack of atypical side effects and new routes in schizophrenia research. Br J Psychiatry 1994;164(2):141-8.
9. Gerlach J, Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacol 1995;10(Suppl 3):39-48.
10. Waddington JL, O'Callaghan E. What makes an antipsychotic 'atypical'? conserving the definition. Cent Nerv Sys Drugs 1997; 7:341-6.
11. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996;57(Suppl 11):68-71.
12. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formulation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140-4.
13. 4. Neuropsychopharmacology 1992;7(4):261-84.
14. Schmauss C, Emrich HM. Dopamine and the action of opiates: a re-evaluation of the dopamine hypothesis with special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia. Biol Psychiatry 1985;20(11):1211-31.
15. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Vibeke Christensen A, editors. Psychopharmacology: current trends. Berlin: Springer; 1988. p. 74-93.
16. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 1984; 141(6):748-52.
17. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45(4):75-91.
18. 2 dopamine receptor occupancy in patients treated with classical antipsychotics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49(7):538-44.
19. 2-receptor occupancy in relation to antipsychotic drug effects - a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33(4):227-35.
20. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153(7):948-50.
21. McEvoy JP, Hogarty GE, Steingard S. Optimal dosing of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48(8):739-45.
22. Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med 1994;24(2): 307-316.
23. Stone CK, Carve DL, Griffith J, Hirschowitz J, Bennett J. Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 1995;152(8):1210-2.
24. Naber D, Hippius H. The European experience with use of clozapine. Hosp Community Psychiatry 1990;41(8):886-90.
25. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96.
26. Herrera JM, Costa J, Sramek J, Heh C. Clozapine in refractory schizophrenia: preliminary findings. Schizophr Res 1988;1(14): 305-6.
27. Conley RR, Schulz CS, Baker RW, Collins JF, Bell JA. Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol Bull 1988;24(2):269-73.
28. Breir A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151(1):20-6.
29. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53(12):1090-7.
30. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337(12):809-15.
31. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH. Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49(5):343-53.
32. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34(10):702-12.
33. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic patients. Neuropsychopharmacology 1996;15(4):361-9.
34. Fujii DE, Ahmed I, Jokumsen M, Compton JM. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci 1997;9(2):240-5.
35. Juul Povlsen U, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71(2):176-85.
36. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994;55(Suppl B):107-9.
37. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics: a retro- and prospective study of extrapyramidal side effects. Psychopharmacology 1996;124(1-2): 188-96.
38. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992;160(Suppl 17):5S-11S.
39. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic patients with schizophrenia. Arch Gen Psychiatry 1997;54(6):567-72.
40. 1 values. J Pharmacol Exp Ther 1989a;251(1):238-46.
41. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989b;25(3):390-2.
42. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153(4):466-76.
43. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 1998;3(2):135-40.
44. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57(10):103-7.
45. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1988; 155(7):921-8.
46. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152(10):1444-9.
47. 2A receptor binding of different doses of quetiapine in schizophrenia [presentation]. American College of Neuropsychopharmacology, 36th Annual meeting; 1997 Dec 8-12, Waikola, Hawaii.
48. Waddington JL, Scully PJ, O'Callaghan E. The new antipsychotics and their potential for early intervention in schizophrenia. Schizophr Res 1997;28(2-3):207-22.
49. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15(Suppl 1):45-51.
50. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-9.
51. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Anderson SW, Beasley C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-18.
52. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized double-blind trial. Am J Psychiatry 1998;155(4):499-504.
53. Gillis MC, editor. Compendium of Pharmaceuticals and Specialties, 33rd ed. Ottawa: Canadian Pharmaceutical Association; 1998.
54. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine in treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41(8):850-4.
55. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990; 41(8):882-5.
56. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150(11):1630-8.
57. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995;92(3):199-201.
58. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(4 Suppl):1S-6S.
59. Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry; 43(2 Suppl):25S-43S
60. Emsley RA, McCreadie R, Livingston M, De Smedt G, Lemmens P. Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multicenter study [presentation]. 8th European Conference of Neuropsychopharmacology; 1995 October; Venice, Italy.
61. Sanger TM, Lieberman JA, Tohen M, Tollefson GD. Olanzapine versus haloperidol in the treatment of first episode psychosis [presentation]. 9th Biennial Workshop on Schizophrenia; 1998 February 7-13; Davos, Switzerland.
62. Lieberman J, Jody D, Geisler S, Vital-Herne J, Alvir JM, Walsleben J, Woerner MG, 1989. Treatment outcome of first episode schizophrenia. Psychopharmacol Bull 1989;25(1):92-6.
63. Fleishhacker WW, Linkz CGG, Hurst BC. ICI 204636 ('Seroquel') - a putative new atypical antipsychotic: results from phase III trials. Schizophr Res 1996;18(2-3):132.
64. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42(4):233-46.
65. Casey DE. Seroquel (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996;5(8):939-57.
66. Awad AG. Subjective response to antipsychotics in schizophrenia. Schizophr Bull 1993;19(3):609-18.
67. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8(4 Suppl):21S-26S.
68. O'Hara P, Brugha TS, Lesage A, Wing J. New findings on tardive dyskinesia in a community sample. Psychol Med 1993; 23(2):453-6.
69. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogarts B, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994;151(10):1430-6.
70. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet 1994;344:1434.
71. Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995;345:456-7.
72. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17(2):325-51.
73. Locbel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149(9):1183-8.
74. Wyatt RJ. Early intervention for schizophrenia: can the course of the illness be altered? Biol Psychiatry 1995;38(1):1-3.
75. Scully PJ, Coakley G, Kinsella A, Waddington JL. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol Med 1997;27(6):1303-10.
76. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28(2):213-8.
77. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13(1):25-40.
78. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88(6):395-402.
79. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995;91(4):271-7.
80. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6):825-35.
81. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166(6):712-26.
82. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14(27):111-23.
83. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154(4):457-65.
84. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96(4):265-73.
85. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic in patients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85(4): 295-305.
86. Fogelson DL, Sternbach H, Payne D. A naturalistic pilot study comparing haloperidol, clozapine, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1997;17(6):492-4.
87. Cavallaro R, Colombo C, Smeraldi E. A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Hum Psychopharmacol 1995;10(3):231-4.
88. Smith RC, Chua JW, Lipetsker B, Bhattacharyya A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 1996;57(10):460-6.
89. Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching in patients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47(12):1382-4.
90. Mok H, Yatham LN. Response to clozapine as a predictor of risperidone response in schizophrenia. Am J Psychiatry 1994; 151(9):1393-4.
91. Lacey RL, Preskorn SH, Jerkovich GS. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? Am J Psychiatry 1995;152(9):1401.
92. Avnon M, Kunin A. Risperidone response after no clozapine response. Br J Psychiatry 1995;167(5):699.
93. Perkins DO, Lieberman JA. Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. Am J Psychiatry 1998;155(2):272-6.
94. Weiden PJ, Olfson M. The cost of relapse in schizophrenia. Schizophr Bull 1995;21(3):419-29.
95. Weiden P, Aquila R, Standard J. Atypical antipsychotics and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57(Suppl 11):53-60.
96. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilised option. J Clin Psychiatry 1992;53(12):426-33.
97. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments in schizophrenia. Schizophr Bull 1991;17(2):217-45.
98. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992;18(3):515-42.
99. Fink M, Sackeim HA. Convulsive therapy in schizophrenia? Schizophr Bull 1996;22(1):27-39.
100. Meltzer HY. Duration of clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 1989;46:672.
101. Wilson WH. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry 1996;153(7):951-2.